New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 16, 2014
10:25 EDTSNY, SNY, SNY, SGEN, SGEN, SGEN, RHHBY, RHHBY, RHHBY, PCYC, PCYC, PCYC, NVS, NVS, NVS, MRK, MRK, MRK, JNJ, JNJ, JNJ, INFI, INFI, INFI, IMGN, IMGN, IMGN, GILD, GILD, GILD, CELG, CELG, CELG, BMY, BMY, BMY, BLUE, BLUE, BLUE, AMGN, AMGN, AMGN, ABBV, ABBV, ABBVLeerink pharma and biotech analysts hold an analyst/industry conference call
Biotech and Pharmaceuticals Analysts provide an update on GU cancer, in conjunction with the upcoming ASCO Annual Meeting, where relevant companies ABBV, AMGN, BLUE, BMY, CELG, GILD, IMGN, INFI, JNJ, MRK, NVS, PCYC, RHHBY, SGEN and SNY may be discussed on the Analyst/Industry conference call to be held on May 23 at 11 am.
News For ABBV;AMGN;BLUE;BMY;CELG;GILD;IMGN;INFI;JNJ;MRK;NVS;PCYC;RHHBY;SGEN;SNY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | 6 | 7 | all recent news | >>
November 11, 2014
08:10 EDTMRKMerck reports results from Phase 2 study of Grazoprevir/Elbasvir
Subscribe for More Information
08:07 EDTGILDGilead announces results from Phase 2 and 3 studies evaluating Harvoni
Subscribe for More Information
08:05 EDTGILDGilead announces data from Phase 2 Sofosbuvir plus GS-5816 studies
Subscribe for More Information
05:26 EDTSNYRegeneron, Sanofi announce dupilumab Phase 2b study met primary endpoint
Subscribe for More Information
November 10, 2014
16:07 EDTRHHBY, NVSUBS to hold a conference
UBS European Conference is being held in London, England on November 11-12.
16:00 EDTGILDOptions Update; November 10, 2014
Subscribe for More Information
15:57 EDTNVSWorldwide Business Research to hold a conference
ProcureCon for Digital & Marketing Services 2014 is being held in San Antonio on November 11-13.
15:54 EDTAMGN, SNYAmerican Society of Nephrology to hold a conference
Subscribe for More Information
15:53 EDTSGEN, BMYCredit Suisse to hold a conference
Healthcare Conference is being held in Scottsdale, Arizona on November 10-13 with webcasted company presentations to begin on November 11 at 10:30 am; not all company presentations may be webcasted. Webcast Link
09:35 EDTGILDActive equity options trading
Subscribe for More Information
09:20 EDTGILD, MRKOn The Fly: Pre-market Movers
Subscribe for More Information
08:48 EDTMRK, GILDGilead rises after Merck presents data on HCV combo
Subscribe for More Information
07:44 EDTJNJJohnson & Johnson looks for acquisitions to help expand in China, WSJ says
Subscribe for More Information
07:20 EDTGILD, MRKGilead overhang from Merck HCV combo removed, says Wells Fargo
Subscribe for More Information
07:19 EDTCELGCredit Suisse to hold a conference
Subscribe for More Information
07:08 EDTBLUEbluebird bio names James DeTore as CFO, treasurer
Subscribe for More Information
November 9, 2014
18:58 EDTMRKMerck presents interim data from C-SWIFT study
Merck announced the presentation of interim data from the C-SWIFT study exploring the potential of a candidate triple-therapy regimen consisting of the fixed-dose combination of grazoprevir/elbasvir , the company’s investigational NS3/4A protease inhibitor and NS5A inhibitor, in combination with sofosbuvir, a nucleotide inhibitor for the treatment of chronic hepatitis C virus, HCV, infection. Preliminary findings in treatment-naïve HCV genotype 1- infected non-cirrhotic patients, following six and four weeks of treatment, and patients with cirrhotic disease, following eight and six weeks of treatment, will be presented by Dr. Eric Lawitz, vice president, scientific and research development, The Texas Liver Institute, San Antonio, TX and C-SWIFT lead investigator. This poster presentation is part of a late-breaking abstract session at the 65th American Association for the Study of Liver Diseases, AASLD, Annual Meeting, also known as The Liver Meeting. “These interim data provide a compelling proof-of-concept for the potential of an eight- or six-week triple therapy course in treatment-naive patients with genotype 1 disease, including cirrhotic patients,” said Dr. Lawitz. “These findings will inform the design of larger studies aimed at understanding the potential of short-duration triple therapy across multiple patient types.”
15:45 EDTBMYBristol-Myers announces daclatasvir data from the UNITY trial program
Subscribe for More Information
12:40 EDTBMYBristol-Myers announces data from ALLY trial investigating daclatasvir
Subscribe for More Information
11:45 EDTBMYBristol-Myers announces data from the UNITY trial program
Subscribe for More Information
1 | 2 | 3 | 4 | 5 | 6 | 7 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use